Yi-Jun Hua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yi-Jun Hua has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Ming-Yuan Chen
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China; Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou 510060, P.R. China
9 shared publications Xiong Zou
Department of Nasopharyngeal Carcinoma Sun Yat‐Sen University Cancer Center Guangzhou China
9 shared publicationsRui You
Nasopharyngeal Cancer Center The Fifth Affiliated Hospital, Sun Yat‐Sen University Zhuhai China
7 shared publicationsSi-Yuan Chen
Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China
7 shared publicationsYou-Ping Liu
Department of Nasopharyngeal Carcinoma, The Fifth Affiliated Hospital Sun Yat-sen University, Zhuhai 519000, P.R. China
6 shared publicationsPei-Yu Huang
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China
5 shared publications
Latest Publications
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSE: To provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregional consolidation, and salvage local therapy for patients with recurrent and/or metastatic nasopharyngeal carcinoma (NPC). METHODS: A multidisciplinary Expert Panel convened by CSCO and ASCO reviewed evidence from randomized trials, meta-analyses, systematic reviews, prospective and retrospective studies, and clinical experience. The guideline was informed by a systematic literature review and consensus-based interpretation of efficacy, safety, feasibility, and patient-centered outcomes across scenarios. Outcomes included overall and progression-free survival, response and disease control rates, toxicity, and quality of life. RESULTS: Evidence supports platinum-based chemotherapy plus a programmed cell death protein 1 (PD-1) inhibitor as preferred first-line therapy for medically fit patients. Evidence also supports maintenance strategies after disease control, while treatment selection depends on prior treatment, disease extent, patient fitness, resource availability, and preferences. Selected responders may receive locoregional consolidation radiotherapy or oral maintenance chemotherapy. For isolated locoregional recurrence amenable to local therapy, options include salvage surgery and re-irradiation. RECOMMENDATIONS: Chemotherapy plus a PD-1 inhibitor, followed by maintenance PD-1 inhibition for up to 2 years, should be offered first-line to appropriate patients with recurrent and/or metastatic NPC. Chemotherapy alone may be offered when immunotherapy is unsuitable or declined. Selected patients responding to first-line chemotherapy may receive oral maintenance chemotherapy or locoregional consolidation intensity-modulated radiotherapy. Salvage surgery or re-irradiation is recommended for appropriately selected patients with isolated locoregional recurrence. Subsequent-line options include chemotherapy, PD-1 inhibitors, and antibody-drug conjugates. Treatment should be individualized according to disease setting, prior therapy, expected toxicities, availability, local drug approvals, and patient preferences. Early supportive and specialist interdisciplinary palliative care, where available, should accompany active anticancer treatment for advanced, incurable disease. Additional information is available at www.ascopubs.org/topics/asco-guidelines/head-neck-cancer .
- 26 August 2026
- Published by Wiley in The Laryngoscope
A Surgical Map Defining High‐Risk Anatomical Boundaries for Salvage Endoscopic Nasopharyngectomy
Objective: Salvage endoscopic nasopharyngectomy has emerged as a viable option for selected patients with recurrent nasopharyngeal carcinoma. However, the absence of an evidence‐based anatomical framework to guide surgical decision‐making limits optimal patient selection and contributes to postoperative recurrence. Methods: We retrospectively analyzed 421 patients with recurrent nasopharyngeal carcinoma who underwent salvage endoscopic nasopharyngectomy between January 2012 and December 2023. Tumor invasion patterns were systematically assessed to identify anatomical sites independently associated with local recurrence, which were subsequently integrated into a surgical map defining high‐risk anatomical boundaries. Results: With a median follow‐up of 46.0 months, the 5‐year overall survival and local recurrence‐free survival were 79.8% and 68.2%, respectively. Multivariable analysis identified several anatomical regions significantly associated with inferior local recurrence‐free survival, including tumor proximity to the internal carotid artery (< 0.5 cm [HR, 2.813; 95% CI, 1.471–5.380]), pterygomaxillary fossa (HR, 3.181; 95% CI, 1.478–6.845), sphenoid sinus (HR, 3.080; 95% CI, 1.307–7.259), posterior cortex of the clivus (HR, 1.906; 95% CI, 1.021–3.560), foramen lacerum (HR, 2.354; 95% CI, 1.281–4.325), and inferior tumor extension below the axis (HR, 4.611; 95% CI, 1.713–12.410). Patients with involvement of these high‐risk areas exhibited markedly lower 5‐year overall survival (64.3% vs. 85.8%; p < 0.001) and local recurrence‐free survival (26.1% vs. 85.1%; p < 0.001) compared with those without high‐risk features. Based on these findings, an evidence‐based surgical map was constructed. Conclusion: We propose a surgical map that defines high‐risk anatomical boundaries for salvage endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma. This framework provides a practical decision‐support tool to improve oncologic outcomes. Level of Evidence: 3.
- 26 August 2026
- Published by Wiley in The Laryngoscope
A Surgical Map Defining High‐Risk Anatomical Boundaries for Salvage Endoscopic Nasopharyngectomy
Objective: Salvage endoscopic nasopharyngectomy has emerged as a viable option for selected patients with recurrent nasopharyngeal carcinoma. However, the absence of an evidence‐based anatomical framework to guide surgical decision‐making limits optimal patient selection and contributes to postoperative recurrence. Methods: We retrospectively analyzed 421 patients with recurrent nasopharyngeal carcinoma who underwent salvage endoscopic nasopharyngectomy between January 2012 and December 2023. Tumor invasion patterns were systematically assessed to identify anatomical sites independently associated with local recurrence, which were subsequently integrated into a surgical map defining high‐risk anatomical boundaries. Results: With a median follow‐up of 46.0 months, the 5‐year overall survival and local recurrence‐free survival were 79.8% and 68.2%, respectively. Multivariable analysis identified several anatomical regions significantly associated with inferior local recurrence‐free survival, including tumor proximity to the internal carotid artery (< 0.5 cm [HR, 2.813; 95% CI, 1.471–5.380]), pterygomaxillary fossa (HR, 3.181; 95% CI, 1.478–6.845), sphenoid sinus (HR, 3.080; 95% CI, 1.307–7.259), posterior cortex of the clivus (HR, 1.906; 95% CI, 1.021–3.560), foramen lacerum (HR, 2.354; 95% CI, 1.281–4.325), and inferior tumor extension below the axis (HR, 4.611; 95% CI, 1.713–12.410). Patients with involvement of these high‐risk areas exhibited markedly lower 5‐year overall survival (64.3% vs. 85.8%; p < 0.001) and local recurrence‐free survival (26.1% vs. 85.1%; p < 0.001) compared with those without high‐risk features. Based on these findings, an evidence‐based surgical map was constructed. Conclusion: We propose a surgical map that defines high‐risk anatomical boundaries for salvage endoscopic nasopharyngectomy in recurrent nasopharyngeal carcinoma. This framework provides a practical decision‐support tool to improve oncologic outcomes. Level of Evidence: 3.
- 13 August 2026
- Published by Elsevier in Oral Oncology
- Vol. 181
Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma
- 13 August 2026
- Published by Elsevier in Oral Oncology
- Vol. 181
Association of glycaemic control with post-radiation nasopharyngeal necrosis in diabetic patients with nasopharyngeal carcinoma
- Open Access
- 29 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Predictive value of nasopharyngeal microbiota for necrosis after re-irradiation in recurrent nasopharyngeal carcinoma
Background: Post-radiation nasopharyngeal necrosis (PRNN) is a severe complication following re-irradiation in patients with recurrent nasopharyngeal carcinoma (NPC). This study aimed to explore the association between nasopharyngeal microbiota and PRNN in patients with recurrent NPC undergoing re-irradiation and to evaluate the predictive value of the microbiota for PRNN. Methods: This retrospective study collected data from 113 patients with recurrent NPC who underwent re-irradiation at the Sun Yat-sen University Cancer Center (SYSUCC) between January 2020 and November 2022. Patients were divided into necrosis and non-necrosis groups based on the development of necrosis after re-irradiation. 5R 16S rRNA sequencing of nasopharyngeal biopsy tissues conducted before re-irradiation was used to assess microbiota composition, diversity, and functional predictions. Clinical features and selected microbial markers were used in a random forest model to predict the occurrence of PRNN. Results: Of the 113 patients with recurrent NPC who underwent re-irradiation, 60 developed PRNN, while 53 did not. Proteobacteria and Firmicutes were the dominant phyla in the nasopharyngeal microbiota of all the patients with recurrent NPC. The necrosis group exhibited significantly higher alpha diversity and distinct beta diversity than the non-necrosis group did. A predictive model that combined clinical features (gross tumor volume [GTV]) with microbiome characteristics achieved an AUC of 87.9% in the training set and 86.9% in the test set, demonstrating robust predictive performance. Conclusions: Nasopharyngeal microbial diversity prior to re-irradiation was significantly higher in the necrosis group. Our predictive model, integrating clinical and microbial features, demonstrated strong performance in predicting PRNN and offers a promising tool for early intervention and prevention strategies.
- 29 September 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-14
Open AccessPredictive value of nasopharyngeal microbiota for necrosis after re-irradiation in recurrent nasopharyngeal carcinoma
Background: Post-radiation nasopharyngeal necrosis (PRNN) is a severe complication following re-irradiation in patients with recurrent nasopharyngeal carcinoma (NPC). This study aimed to explore the association between nasopharyngeal microbiota and PRNN in patients with recurrent NPC undergoing re-irradiation and to evaluate the predictive value of the microbiota for PRNN. Methods: This retrospective study collected data from 113 patients with recurrent NPC who underwent re-irradiation at the Sun Yat-sen University Cancer Center (SYSUCC) between January 2020 and November 2022. Patients were divided into necrosis and non-necrosis groups based on the development of necrosis after re-irradiation. 5R 16S rRNA sequencing of nasopharyngeal biopsy tissues conducted before re-irradiation was used to assess microbiota composition, diversity, and functional predictions. Clinical features and selected microbial markers were used in a random forest model to predict the occurrence of PRNN. Results: Of the 113 patients with recurrent NPC who underwent re-irradiation, 60 developed PRNN, while 53 did not. Proteobacteria and Firmicutes were the dominant phyla in the nasopharyngeal microbiota of all the patients with recurrent NPC. The necrosis group exhibited significantly higher alpha diversity and distinct beta diversity than the non-necrosis group did. A predictive model that combined clinical features (gross tumor volume [GTV]) with microbiome characteristics achieved an AUC of 87.9% in the training set and 86.9% in the test set, demonstrating robust predictive performance. Conclusions: Nasopharyngeal microbial diversity prior to re-irradiation was significantly higher in the necrosis group. Our predictive model, integrating clinical and microbial features, demonstrated strong performance in predicting PRNN and offers a promising tool for early intervention and prevention strategies.
- Open Access
- 5 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Nasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples
Background: Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, which include EBV related biomarkers. However, the advances achieved still remain imperfection. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in nasopharyngeal carcinoma (NPC) patients. Methods: A total of 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was used to evaluate the methylation levels of three genes (SEPTIN9, RASSF1A, and H4C6) in swabs and plasma samples. The methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results: The detection rate of methylated SEPTIN9, RASSF1A, and H4C6 in nasopharyngeal swabs of patients with newly diagnosed NPC was 88.2%, 92.9% and 71.8%, respectively, while it reduced to 54.3%, 42.9% and 45.7% in blood plasma. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to distinguish between untreated NPC and healthy controls was 88%, 93%, and 72%, respectively. Methylated RASSF1A showed the highest classification accuracy (AUC = 0.956). The detection rate of the methylated target genes was considerably lower in paired plasma samples. Conclusion: The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential for NPC diagnosis.
- 5 July 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Open AccessNasopharyngeal carcinoma detected noninvasively in the real world using three gene methylation analyses from automatically processed bilateral nasal swab samples
Background: Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, which include EBV related biomarkers. However, the advances achieved still remain imperfection. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in nasopharyngeal carcinoma (NPC) patients. Methods: A total of 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was used to evaluate the methylation levels of three genes (SEPTIN9, RASSF1A, and H4C6) in swabs and plasma samples. The methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results: The detection rate of methylated SEPTIN9, RASSF1A, and H4C6 in nasopharyngeal swabs of patients with newly diagnosed NPC was 88.2%, 92.9% and 71.8%, respectively, while it reduced to 54.3%, 42.9% and 45.7% in blood plasma. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to distinguish between untreated NPC and healthy controls was 88%, 93%, and 72%, respectively. Methylated RASSF1A showed the highest classification accuracy (AUC = 0.956). The detection rate of the methylated target genes was considerably lower in paired plasma samples. Conclusion: The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential for NPC diagnosis.
- Open Access
- 23 December 2024
- Published by AccScience Publishing in Cancer Plus
- Vol. 6 (4) , 4023
Incidence of mastoiditis in nasopharyngeal carcinoma following anti-PD-1 therapy: A propensity-matched analysis
Mastoiditis can be induced by radiotherapy and is closely associated with hearing loss. This study aimed to investigate the incidence of mastoiditis in patients with locally advanced nasopharyngeal carcinoma (LANPC) undergoing anti-programmed death 1 (PD-1) therapy. We retrospectively reviewed patients with primary locoregionally advanced nasopharyngeal carcinoma who received intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy with or without anti-PD-1 therapy from January 2020 to January 2022 in a single medical institution. Group A received neoadjuvant chemotherapy (NACT) + concurrent chemoradiotherapy (CCRT) + anti-PD-1 therapy, whereas Group B received the same treatment, except for anti-PD-1 therapy. We employed a propensity score matching method to match patients from each group in a 1:1 ratio. The severity of mastoiditis was assessed using magnetic resonance imaging, specifically grading mastoid opacification on a scale of 0 – 3. A total of 136 out of 259 eligible patients were propensity-matched, with 68 patients in Group A and 68 patients in Group B. No significant differences were observed in patient and tumor characteristics between the two groups. There were no significant differences in the incidence rates of severe mastoiditis between the two groups before NACT, before CCRT, at 0 months, and at 3 months following CCRT. However, the incidence rate of severe mastoiditis at 6 months following CCRT was significantly higher in Group A compared to Group B (35.3% vs. 20.6%, P = 0.008). Analysis of variance with repeated measures demonstrated that anti-PD-1 therapy did not increase the incidence rate of severe mastoiditis in LANPC patients compared to immunotherapy-free patients following CCRT (P = 0.24). LANPC patients receiving anti-PD-1 therapy did not significantly experience more severe mastoiditis during CCRT, but there was an increasing trend post-CCRT. Additional follow-up with a larger patient cohort is necessary to draw definitive conclusions.
- 23 December 2024
- Published by AccScience Publishing in Cancer Plus
- Vol. 6 (4) , 4023
Open AccessIncidence of mastoiditis in nasopharyngeal carcinoma following anti-PD-1 therapy: A propensity-matched analysis
Mastoiditis can be induced by radiotherapy and is closely associated with hearing loss. This study aimed to investigate the incidence of mastoiditis in patients with locally advanced nasopharyngeal carcinoma (LANPC) undergoing anti-programmed death 1 (PD-1) therapy. We retrospectively reviewed patients with primary locoregionally advanced nasopharyngeal carcinoma who received intensity-modulated radiotherapy and concurrent cisplatin-based chemotherapy with or without anti-PD-1 therapy from January 2020 to January 2022 in a single medical institution. Group A received neoadjuvant chemotherapy (NACT) + concurrent chemoradiotherapy (CCRT) + anti-PD-1 therapy, whereas Group B received the same treatment, except for anti-PD-1 therapy. We employed a propensity score matching method to match patients from each group in a 1:1 ratio. The severity of mastoiditis was assessed using magnetic resonance imaging, specifically grading mastoid opacification on a scale of 0 – 3. A total of 136 out of 259 eligible patients were propensity-matched, with 68 patients in Group A and 68 patients in Group B. No significant differences were observed in patient and tumor characteristics between the two groups. There were no significant differences in the incidence rates of severe mastoiditis between the two groups before NACT, before CCRT, at 0 months, and at 3 months following CCRT. However, the incidence rate of severe mastoiditis at 6 months following CCRT was significantly higher in Group A compared to Group B (35.3% vs. 20.6%, P = 0.008). Analysis of variance with repeated measures demonstrated that anti-PD-1 therapy did not increase the incidence rate of severe mastoiditis in LANPC patients compared to immunotherapy-free patients following CCRT (P = 0.24). LANPC patients receiving anti-PD-1 therapy did not significantly experience more severe mastoiditis during CCRT, but there was an increasing trend post-CCRT. Additional follow-up with a larger patient cohort is necessary to draw definitive conclusions.
- Open Access
- 22 October 2024
- Published by Springer Nature in Research Square
Noninvasive detection of early nasopharyngeal carcinoma based on three gene methylation analysis in bilateral nasal swab samples processed automatically
Background Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, including EBV related biomarkers. However, the advances achieved still remain imperfect. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in patients with nasopharyngeal carcinoma (NPC). Methods 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was carried out to evaluate the methylation status of three genes (SEPTIN9, RASSF1A, and H4C6) in the swabs and plasma samples. Methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results In the nasopharyngeal swabs of patients with newly diagnosed NPC, the detection rate of methylated SEPTIN9, RASSF1A, and H4C6 was 88.2%, 92.9% and 71.8%, while the rate decreased to 54.3%, 42.9% and 45.7% by blood plasma, respectively. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to differentiate between untreated NPC, and treated NPC plus healthy controls was 88%, 93%, and 72%. Methylated RASSF1A showed the best classification accuracy (AUC = 0.956). The detection rate of the target methylated genes was significantly lower in the paired plasma samples. Conclusion The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential in NPC diagnosis.
- 22 October 2024
- Published by Springer Nature in Research Square
Open AccessNoninvasive detection of early nasopharyngeal carcinoma based on three gene methylation analysis in bilateral nasal swab samples processed automatically
Background Efforts have been made to improve the performance of nasopharyngeal carcinoma screening strategies, including EBV related biomarkers. However, the advances achieved still remain imperfect. DNA methylation occurs early in cancer development and can be used as potential diagnostic biomarker. This study aimed to investigate the diagnostic performance of three methylated genes in patients with nasopharyngeal carcinoma (NPC). Methods 255 nasopharyngeal swabs and 35 plasma samples were collected from patients with newly diagnosed or treated NPC and healthy controls. Methylation-specific PCR (MSP) was carried out to evaluate the methylation status of three genes (SEPTIN9, RASSF1A, and H4C6) in the swabs and plasma samples. Methylation rates, sensitivity, and specificity of the candidate genes were calculated. Furthermore, the detectability of methylated genes in paired swabs and plasma was compared. Results In the nasopharyngeal swabs of patients with newly diagnosed NPC, the detection rate of methylated SEPTIN9, RASSF1A, and H4C6 was 88.2%, 92.9% and 71.8%, while the rate decreased to 54.3%, 42.9% and 45.7% by blood plasma, respectively. The sensitivity of detecting methylated SEPTIN9, RASSF1A, and H4C6 to differentiate between untreated NPC, and treated NPC plus healthy controls was 88%, 93%, and 72%. Methylated RASSF1A showed the best classification accuracy (AUC = 0.956). The detection rate of the target methylated genes was significantly lower in the paired plasma samples. Conclusion The detection of RASSF1A methylation through non-invasive nasopharyngeal cavity swab sampling demonstrates significant potential in NPC diagnosis.
- Open Access
- 15 October 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (10) , 101779
A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma
- 15 October 2024
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (10) , 101779
Open AccessA phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma
- 17 December 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (2) , 447-456
Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients
Objective: Postradiation nasopharyngeal necrosis (PRNN) frequently develops after second‐course radiotherapy for nasopharyngeal carcinoma (NPC). PRNN can lead to internal carotid artery (ICA) massive hemorrhage due to ICA rupture, resulting in sudden death. This study aims to explore the pretreatment of the ICA to prevent fatal massive hemorrhage in PRNN patients.Study Design: Retrospective cohort study.Setting: Sun Yat‐sen University Cancer Center.Methods: Patients diagnosed with NPC and PRNN from January 2010 to September 2022 were included. The Cox proportional hazards regression analysis was performed to analyze risk factors for massive hemorrhage and survival. A nomogram was developed to integrate prognostic models and perform parameter calibration.Results: Two hundred and fifty‐four PRNN patients were included in this study. Prophylactic ICA occlusion significantly reduced the risk of ICA hemorrhage compared to no prophylactic ICA occlusion (3.6% vs 40.6%, P < .001). Surgical repair on necrosis significantly prevented hemorrhage and improved survival. The nomogram, incorporating the above 2 factors and the nearest distance from necrosis to ICA ≤ 3 mm, exhibited excellent discriminative ability for hemorrhage. We identified 3 high‐risk factors that indicate the need for prophylactic ICA management in PRNN patients: (1) exposure of ICA by rhinoscopy; (2) signs of ICA erosion on MRA scanning; (3) the depth of soft tissue coverage surrounding the ICA wall within the necrotic cavity is less than 3 mm on magnetic resonance imaging.Conclusion: We have identified 3 high‐risk factors for PRNN patients that necessitate prophylactic ICA management. These findings are expected to contribute to improving the quality of life and overall survival of PRNN patients.
- 17 December 2023
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (2) , 447-456
Assessment of Prophylactic Internal Carotid Artery Management in Postradiation Nasopharyngeal Necrosis Patients
Objective: Postradiation nasopharyngeal necrosis (PRNN) frequently develops after second‐course radiotherapy for nasopharyngeal carcinoma (NPC). PRNN can lead to internal carotid artery (ICA) massive hemorrhage due to ICA rupture, resulting in sudden death. This study aims to explore the pretreatment of the ICA to prevent fatal massive hemorrhage in PRNN patients.Study Design: Retrospective cohort study.Setting: Sun Yat‐sen University Cancer Center.Methods: Patients diagnosed with NPC and PRNN from January 2010 to September 2022 were included. The Cox proportional hazards regression analysis was performed to analyze risk factors for massive hemorrhage and survival. A nomogram was developed to integrate prognostic models and perform parameter calibration.Results: Two hundred and fifty‐four PRNN patients were included in this study. Prophylactic ICA occlusion significantly reduced the risk of ICA hemorrhage compared to no prophylactic ICA occlusion (3.6% vs 40.6%, P < .001). Surgical repair on necrosis significantly prevented hemorrhage and improved survival. The nomogram, incorporating the above 2 factors and the nearest distance from necrosis to ICA ≤ 3 mm, exhibited excellent discriminative ability for hemorrhage. We identified 3 high‐risk factors that indicate the need for prophylactic ICA management in PRNN patients: (1) exposure of ICA by rhinoscopy; (2) signs of ICA erosion on MRA scanning; (3) the depth of soft tissue coverage surrounding the ICA wall within the necrotic cavity is less than 3 mm on magnetic resonance imaging.Conclusion: We have identified 3 high‐risk factors for PRNN patients that necessitate prophylactic ICA management. These findings are expected to contribute to improving the quality of life and overall survival of PRNN patients.